Gilead Sciences, Inc. (GILD)
After hours:
| Previous Close | 84.17 |
| Open | 84.30 |
| Bid | 84.43 x 1000 |
| Ask | 84.72 x 1000 |
| Day's Range | 83.98 - 84.95 |
| 52 Week Range | 62.07 - 87.87 |
| Volume | |
| Avg. Volume | 6,548,460 |
| Market Cap | 105.314B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 103.16 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (3.64%) |
| Ex-Dividend Date | Sept 13, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead Sciences, (Nasdaq: GILD)), a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income countries (LMICs). This agreement will broaden access to lenacapavir, the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to
- Business Wire
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
FOSTER CITY, Calif., October 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries. The agreements were signed in advance of any global regulatory submissions to enable these countries
- ACCESSWIRE
Championing HIV Services for LGBTQ+ Youth
NORTHAMPTON, MA / ACCESSWIRE / September 25, 2024 / Gilead Sciences As a young gay professional, Terrell Parker spent several years working at the National Minority AIDS Council in Washington, D.C. during his 20s, advocating to help end the HIV epidemic ...
